- Home
- DTIL vs ADAG Comparison
DTIL vs ADAG Comparison
Compare DTIL & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTIL | ADAG |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.0M | 146.3M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DTIL | ADAG |
|---|---|---|
| Price | $5.83 | $4.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $60.00 | $8.00 |
| AVG Volume (30 Days) | ★ 336.9K | 288.3K |
| Earning Date | 05-14-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | N/A |
| Revenue This Year | N/A | $3,688.61 |
| Revenue Next Year | $34.75 | $17.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $1.34 |
| 52 Week High | $8.82 | $4.72 |
Technical Indicators
Market Signals| Indicator | DTIL | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 54.21 | 55.37 |
| Support Level | $3.96 | $1.69 |
| Resistance Level | $7.59 | $4.58 |
| Average True Range (ATR) | 0.58 | 0.49 |
| MACD | -0.15 | 0.01 |
| Stochastic Oscillator | 21.03 | 42.97 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.